These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36389208)

  • 1. Structural insights into conformational stability and binding of thiazolo-[2,3-b] quinazolinone derivatives with EGFR-TKD and
    Ahmad Mir S; Paramita Mohanta P; Kumar Meher R; Baitharu I; Kumar Raval M; Kumar Behera A; Nayak B
    Saudi J Biol Sci; 2022 Dec; 29(12):103478. PubMed ID: 36389208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD.
    Mir SA; Nayak B
    J Biomol Struct Dyn; 2023 May; 41(8):3702-3716. PubMed ID: 35343861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches.
    Mir SA; Muhammad A; Padhiary A; Ekka NJ; Baitharu I; Naik PK; Nayak B
    J Biomol Struct Dyn; 2023; 41(21):12063-12076. PubMed ID: 36695102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, molecular modeling, and biological evaluations of novel chalcone based 4-Nitroacetophenone derivatives as potent anticancer agents targeting EGFR-TKD.
    Mir SA; Murmu N; Meher RK; Baitharu I; Nayak B; Khan A; Khan MI; Abdulaal WH
    J Biomol Struct Dyn; 2024 Jan; ():1-16. PubMed ID: 38281944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
    Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
    J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
    Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
    Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
    Saini N; Grewal AS; Lather V; Gahlawat SK
    Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
    Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
    Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
    Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
    J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations.
    Eldehna WM; El Hassab MA; Abo-Ashour MF; Al-Warhi T; Elaasser MM; Safwat NA; Suliman H; Ahmed MF; Al-Rashood ST; Abdel-Aziz HA; El-Haggar R
    Bioorg Chem; 2021 May; 110():104748. PubMed ID: 33684714
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Keshari AK; Singh AK; Raj V; Rai A; Trivedi P; Ghosh B; Kumar U; Rawat A; Kumar D; Saha S
    Drug Des Devel Ther; 2017; 11():1623-1642. PubMed ID: 28615927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening.
    Ornnork N; Kiriwan D; Lirdprapamongkol K; Choowongkomon K; Svasti J; Eurtivong C
    J Mol Graph Model; 2020 Sep; 99():107639. PubMed ID: 32534372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring molecular interactions of potential inhibitors against the spleen tyrosine kinase implicated in autoimmune disorders via virtual screening and molecular dynamics simulations.
    Samanta S; Sk MF; Koirala S; Kar P
    SAR QSAR Environ Res; 2023 Oct; ():1-29. PubMed ID: 37881946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 5-bromoindole-2-carboxylic Acid Derivatives as EGFR Inhibitors: Synthesis, Docking Study, and Structure Activity Relationship.
    Hassan OM; Kubba A; Tahtamouni LH
    Anticancer Agents Med Chem; 2023; 23(11):1336-1348. PubMed ID: 36847231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.
    Stein MK; Morris L; Sullivan JL; Fenton M; VanderWalde A; Schwartzberg LS; Martin MG
    Med Oncol; 2017 Jul; 34(7):126. PubMed ID: 28573640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling and simulations of some antiviral drugs, benzylisoquinoline alkaloid, and coumarin molecules to investigate the effects on Mpro main viral protease inhibition.
    Mir SA; Meher RK; Nayak B
    Biochem Biophys Rep; 2023 Jul; 34():101459. PubMed ID: 36987522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
    Kumar A; Kumar B; Bhatia R
    Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.